Literature DB >> 20033846

Phenotypic characteristics and diagnoses of patients referred to an iron overload clinic.

John B Dever1, Mark A Mallory, Julie E Mallory, Dorothy Wallace, Kris V Kowdley.   

Abstract

BACKGROUND: There are limited data on the phenotypic differences between patients with hereditary hemochromatosis (HH) and other forms of iron overload. AIMS: To describe and compare patients suspected of having iron overload disease.
METHODS: Patients were evaluated at a university iron overload clinic over a 5-year period. Biochemical and clinical profiles of patients with HH and non-HH causes of suspected iron overload were retrospectively compared.
RESULTS: A total of 270 patients were evaluated during the enrollment period, and 137 (51%) were diagnosed with HH. The most common reasons for referral were elevated serum iron markers (155 patients), followed by positive family history (40 patients), and known HH (75 patients). In patients without HH referred for suspected iron overload, the most common diagnoses were nonalcoholic fatty liver disease (NAFLD) (24%), chronic hepatitis C infection (14%), and alcohol related liver disease (9%). Of the patients with HH, 108 were C282Y homozygotes, 20 were compound heterozygotes (C282Y/H63D), and nine had neither mutation. The following clinical characteristics were significantly different (p < 0.05) between patients with HH and all other referred patients: arthralgia (42 vs. 16%) and decreased libido (11 vs. 4%). There was a non-significant trend towards increased fatigue (44 vs. 33%), diabetes (10 vs. 6%), impotence (8 vs. 4%), and hypothyroidism (10 vs. 6%) in the HH group.
CONCLUSIONS: (1) A large proportion of patients referred for suspected iron overload have diagnoses other than HH. (2) NAFLD, chronic hepatitis C, and chronic alcohol use were the most common alternative diagnoses. (3) Arthralgia and fatigue are the most common symptoms among patients with HH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033846      PMCID: PMC3481540          DOI: 10.1007/s10620-009-1080-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis.

Authors:  J N Feder; A Gnirke; W Thomas; Z Tsuchihashi; D A Ruddy; A Basava; F Dormishian; R Domingo; M C Ellis; A Fullan; L M Hinton; N L Jones; B E Kimmel; G S Kronmal; P Lauer; V K Lee; D B Loeb; F A Mapa; E McClelland; N C Meyer; G A Mintier; N Moeller; T Moore; E Morikang; C E Prass; L Quintana; S M Starnes; R C Schatzman; K J Brunke; D T Drayna; N J Risch; B R Bacon; R K Wolff
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

2.  A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations.

Authors:  A M Jouanolle; P Fergelot; G Gandon; J Yaouanq; J Y Le Gall; V David
Journal:  Hum Genet       Date:  1997-10       Impact factor: 4.132

3.  The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis.

Authors:  Lyle C Gurrin; Nicholas J Osborne; Clare C Constantine; Christine E McLaren; Dallas R English; Dorota M Gertig; Martin B Delatycki; Melissa C Southey; John L Hopper; Graham G Giles; Gregory J Anderson; John K Olynyk; Laurie W Powell; Katrina J Allen
Journal:  Gastroenterology       Date:  2008-09-13       Impact factor: 22.682

4.  Reference centiles for serum ferritin and percentage of transferrin saturation, with application to mutations of the HFE gene.

Authors:  J A Koziol; N J Ho; V J Felitti; E Beutler
Journal:  Clin Chem       Date:  2001-10       Impact factor: 8.327

5.  The diversity of liver diseases among outpatient referrals for an elevated serum ferritin.

Authors:  Karen Wong; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

6.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

7.  Screening for hemochromatosis by measuring ferritin levels: a more effective approach.

Authors:  Jill Waalen; Vincent J Felitti; Terri Gelbart; Ernest Beutler
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

8.  Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis.

Authors:  Elizabeth D Morrison; David J Brandhagen; Pradyumna D Phatak; James C Barton; Edward L Krawitt; Hashem B El-Serag; Stuart C Gordon; Mark V Galan; Bruce Y Tung; George N Ioannou; Kris V Kowdley
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

9.  Iron-overload-related disease in HFE hereditary hemochromatosis.

Authors:  Katrina J Allen; Lyle C Gurrin; Clare C Constantine; Nicholas J Osborne; Martin B Delatycki; Amanda J Nicoll; Christine E McLaren; Melanie Bahlo; Amy E Nisselle; Chris D Vulpe; Gregory J Anderson; Melissa C Southey; Graham G Giles; Dallas R English; John L Hopper; John K Olynyk; Lawrie W Powell; Dorota M Gertig
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

Review 10.  HFE-associated hereditary hemochromatosis.

Authors:  Jacob Alexander; Kris V Kowdley
Journal:  Genet Med       Date:  2009-05       Impact factor: 8.822

View more
  7 in total

1.  Serum ferritin as a biomarker for NAFLD: ready for prime time?

Authors:  Raj A Shah; Kris V Kowdley
Journal:  Hepatol Int       Date:  2019-02-09       Impact factor: 6.047

Review 2.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 3.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

4.  Study of total stimulated saliva flow and hyperpigmentation in the oral mucosa of patients diagnosed with hereditary hemochromatosis. Series of 25 cases.

Authors:  Miguel-Angel Sánchez-Pablo; Vanesa González-García; Alejandro del Castillo-Rueda
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2012-01-01

5.  HFE genotyping in patients with elevated serum iron indices and liver diseases.

Authors:  Andreia Silva Evangelista; Maria Cristina Nakhle; Thiago Ferreira de Araújo; Clarice Pires Abrantes-Lemos; Marta Mitiko Deguti; Flair José Carrilho; Eduardo Luiz Rachid Cançado
Journal:  Biomed Res Int       Date:  2015-01-14       Impact factor: 3.411

6.  Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

Authors:  Sina Ghandian; Rahul Thapa; Anurag Garikipati; Gina Barnes; Abigail Green-Saxena; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  JGH Open       Date:  2022-03-08

7.  A farewell to phlebotomy-use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report.

Authors:  Yuki Hamada; Eiichi Hirano; Koji Sugimoto; Keizo Hanada; Taiichi Kaku; Naoki Manda; Kenichi Tsuchida
Journal:  J Med Case Rep       Date:  2022-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.